Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2020-07-26 Capital/Financing Update
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Proposed issue of Securities - PTX 7 pages 32.4KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Prescient Therapeutics Limited regarding a proposed issue of securities under a securities purchase plan. It details the number of securities to be issued, offer price, record date, offer closing date, underwriting details, and other terms related to the capital raising. There are no financial statements or comprehensive financial performance data included, and the document focuses on the capital raising event itself. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2020-07-26 English
Section 708A Cleansing Notice 2 pages 85.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Share Purchase Plan – Cleansing Notice' and references compliance with ASIC Corporations Instrument 2019/547 and sections of the Corporations Act 2001 (Cth). It is a notice given to ASX regarding a share purchase plan offer without disclosure requirements. The document does not contain financial statements or detailed financial data but is a regulatory announcement related to capital raising compliance and disclosure. It is not a full financial report, earnings release, or management discussion. The document length is 4571 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it relates to a share purchase plan and compliance notice for capital raising.
2020-07-26 English
Share Purchase Plan Booklet 25 pages 455.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'SHARE PURCHASE PLAN OFFER BOOKLET' and contains detailed terms and conditions for a Share Purchase Plan (SPP) offered by Prescient Therapeutics Limited. It includes information such as the offer price, eligibility, underwriting arrangements, key dates, and instructions for shareholders to participate in the plan. The content is focused on a capital raising activity through issuing new shares to existing shareholders without brokerage fees. There are no financial statements or earnings data presented, nor is this a regulatory announcement or a report publication notice. The document is clearly an offer booklet related to a capital raising event, which fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full offer booklet, not just an announcement or summary.
2020-07-26 English
Trading Halt 2 pages 191.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Prescient Therapeutics Limited regarding a trading halt requested pending a capital raising announcement. It is a short notice about the trading halt and does not contain any financial data, detailed report, or analysis. It is an announcement related to capital raising but does not provide the actual capital/financing update itself. According to the rules, such short announcements about trading halts or pending announcements are classified as Regulatory Filings (RNS) because they do not contain substantive financial or report content.
2020-07-23 English
June 2020 Quarterly Update and Appendix 4C 8 pages 206.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'June 2020 Quarterly Update and Appendix 4C' and includes detailed financial information such as cash flow statements, operating highlights, and business updates for the quarter ended 30 June 2020. It references ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting for entities listed on the Australian Securities Exchange. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, specifically a quarter. It is not merely an announcement or a certification but a comprehensive quarterly financial report including cash flow statements and operational commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2020
2020-07-21 English
2 PTX Assets Chosen in Doherty Institute COVID-19 Program 4 pages 143.7KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Prescient Therapeutics has two assets selected for a COVID-19 antiviral testing program by the Doherty Institute. It discusses the research agreement, testing process, and some background on the company and its therapies. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no earnings data, and no detailed investor presentation content. The document is an announcement of a research collaboration and related intellectual property filings, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report. It is best classified as a general regulatory announcement about company activities and developments that do not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). Confidence is high given the clear nature of the content and absence of financial or governance report elements.
2020-07-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.